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Background and Purpose—An early and reliable prognosis for recovery in stroke patients is important for initiation of
individual treatment and for informing patients and relatives. We recently developed and validated models for predicting
survival and functional independence within 3 months after acute stroke, based on age and the National Institutes of
Health Stroke Scale score assessed within 6 hours after stroke. Herein we demonstrate the applicability of our models
in an independent sample of patients from controlled clinical trials.
Methods—The prognostic models were used to predict survival and functional recovery in 5419 patients from the Virtual
International Stroke Trials Archive (VISTA). Furthermore, we tried to improve the accuracy by adapting intercepts and
estimating new model parameters.
Results—The original models were able to correctly classify 70.4% (survival) and 72.9% (functional recovery) of patients.
Because the prediction was slightly pessimistic for patients in the controlled trials, adapting the intercept improved the
accuracy to 74.8% (survival) and 74.0% (functional recovery). Novel estimation of parameters, however, yielded no
relevant further improvement.
Conclusions—For acute ischemic stroke patients included in controlled trials, our easy-to-apply prognostic models based
on age and National Institutes of Health Stroke Scale score correctly predicted survival and functional recovery after 3
months. Furthermore, a simple adaptation helps to adjust for a different prognosis and is recommended if a large data
set is available. (Stroke. 2008;39:000-000.)
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The importance of an early and reliable prognosis forrecovery in patients with acute stroke is undisputed.1,2 In
addition to clinical reasons, such as information for patients and
family as well as adapting treatment and rehabilitation options,
inclusion of prognostic information in controlled clinical trials
helps to define individual clinical end points, to select suitable
patients, and to reduce required sample sizes.3–5
To be useful and applicable to clinical practice, a prognos-
tic model needs to be validated and easy to implement; ie, it
should contain only a few variables that are readily available
for all patients.6 A systematic review that included studies
until 1997 showed that the methodology of most reported
prognostic models for stroke recovery was poor, and none of
the models was recommended for clinical practice or re-
search.7 Since then, additional prognostic models have been
developed. Of these, the validated models by Baird et al8 and
Johnston et al9–11 that predicted recovery within 3 months
relied on imaging variables, which may not be available for
all patients and in all settings. In contrast, the models by
Counsell et al12 and our own group13 included a few simple
clinical variables and were also subsequently validated.14–16
Because in these models prognostic variables were assessed
within a delay of 4 (median) and 2 to 3 days after stroke,
respectively, timely prediction for initiating acute treatment was
precluded. To allow for an almost immediate prognosis based on
a few simple variables, we recently developed and externally
validated models for predicting survival and functional indepen-
dence within 3 months.17 These models are based on age and
neurologic impairment as measured on the National Institutes of
Health Stroke Scale (NIHSS), assessed within 6 hours after
stroke onset. In the external validation sample,75% of patients
were classified correctly for functional independence and85%
with regard to survival.
In some respects, patients in our previous training and
validation samples were highly comparable: all patients were
admitted consecutively to German neurology departments with
an acute stroke unit. We were therefore able to test the trans-
portability of the models, which constitutes accuracy in different
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but similar populations.18 The aim of the current study was to
demonstrate more stringently the utility of our models by
applying them to patients in the data set of the Virtual Interna-
tional Stroke Trials Archive (VISTA, www.vista.gla.ac.uk/).19
Originating from diverse clinical trials in various countries, the
stroke patients in VISTA differ from our original German Stroke
Study data bank in terms of selection, level of stroke care,
recruitment, and nationality. On the basis of our prognostic
models, we will address the following questions: (1) Are the
prognostic models adequate in this different population? (2) Can
the predictions be relevantly improved by fine-tuning, ie, slight
modifications, of the models? and (3) Can the predictions be
relevantly improved by developing novel models, ie, deriving
new parameter estimates?
Subjects and Methods
Model Development
A description of the development of the models has been detailed
elsewhere.17 In brief, functional independence of the patients was
assessed by the Barthel Index (BI) as one of the most widely used
measures of functional independence. To identify patients who
recovered, as advocated in the guidelines for controlled clinical
trials,20 a cutoff BI value95 versus95 was used. Specifically, the
following 2 models were developed with data from the stroke data
bank of the German Stroke Collaborators13,16,21: (1) model I to
predict functional recovery, ie, BI 95 versus BI 95 or dead and
(2) model II to predict survival versus death (all causes).
From a set of 16 possible predictive variables that had been identified
in a systematic literature search and included single items as well as the
overall score of the NIHSS, logistic regression models were fitted by
forward, backward, and stepwise selection. To model the relation with
continuous variables, fractional polynomials were applied, and possible
2-way interactions were considered. The resulting logistic regression
models showed a higher probability for the less favorable outcome in
both models with higher age and greater overall neurologic impairment,
as measured by the overall NIHSS score assessed within 6 hours after
symptom onset (see Table 1, left column).17
To apply the resulting models, nomograms were created that provide
the estimated probabilities for outcome and the resulting classifications
based on age and NIHSS score of a single patient (see Figure 1).22 To
forecast the outcome for a specific patient, the values of each variable
are marked on the respective lines. For instance, for the functional
recovery model, age is marked on the second line of Figure 1A. Then,
a straight line is drawn upward to determine the points for the variable
“age.” This is repeated for the NIHSS, and the points are summed and
marked in the second to last line “Total Points.” Drawing a line
downward to the lowest line then gives the predicted probability for this
patient to become functionally independent. For example, a patient aged
66 years (15 points) and with an overall NIHSS score of 7 (82 points)
receives a total point score of 97. This corresponds to an estimated
probability of 65% for functional independence. On the basis of the
classification threshold from previous studies, this patient is therefore
predicted to recover functionally. Similarly, application of the survival
model (Figure 1B) results in 109 total points for this patient, correspond-
ing to a 94% probability of survival.
VISTA Data Set
VISTA (www.vista.gla.ac.uk/) was created with the aim of providing
access to patient data to perform exploratory analyses and hypothesis
testing.19 All included trials were approved by institutional review
boards. At the time of data extraction (March 15, 2006), VISTA
encompassed data from 15 000 patients from 21 acute stroke
randomized, controlled trials. For the purpose of this analysis,
relevant data were extracted from 11 trials that met the following
entry criteria: (1) minimum data set of 100 patients; (2) documented
entry criteria; (3) baseline assessment within 24 hours of stroke
onset, including recording of neurologic deficit by NIHSS; (4)
confirmation of stroke diagnosis by cerebral imaging within 7 days;
(5) outcome assessed between 1 and 6 months after stroke onset,
including recording of BI or mortality; and (7) monitoring proce-
dures in practice to validate data. These data represented a total of
5843 patients who had been entered into VISTA after their inclusion
in the respective clinical trials.
Statistical Analyses
For all analyses, patients with missing outcome data were excluded
to allow for an evaluation of the resulting predictions. Patients in the
original data set and in the VISTA data set are described with regard
to age, NIHSS, and sex, and differences in the data sets are presented
as mean differences and 95% CIs based on a t distribution of the
difference (age and NIHSS) and as the difference in proportion with
95% CI, as proposed by Newcombe (method 10).23
To compare the applicability of our prognostic models, 3 different
approaches were taken. In the most stringent approach, the algo-
rithms as described in Figure 1 and Table 1 were applied to all
patients in the VISTA data set for whom complete information on
age and overall NIHSS score was available. The resulting numbers
of correct classifications overall and in each outcome group were
determined. In addition, a receiver operating characteristic was
drawn for each model, which plotted specificity versus sensitivity,
and the area under the curve is presented with its SE.
In the second approach, we aimed to adjust the original models to
optimize the fit in the VISTA data set. For this, it should be remembered
that a logistic regression model for prognosis principally consists of 2
components, the intercept and a set of slope coefficients. If the intercept
is valid in the new data, the model is well calibrated. In contrast, if it is
misspecified, the resulting predicted probabilities are systematically
either too high or too low. On the other hand, if the slope is incorrectly
estimated, the model shows insufficient discrimination in the new data,
and the spread of the predicted probabilities is either too extreme or not
extreme enough, so that the model cannot differentiate between patients
with a more or less favorable outcome.24 In this approach, we wanted to
allow for a different prognosis but assumed that the effects of predictors
would be similar. Therefore, we only aimed at recalibrating the models,
ie, at adjusting the values of the intercept. This was solved technically by
developing a logistic regression model to predict the observed outcomes
in the VISTA data from the linear predictor of the original logistic
regression model. The aims of this new regression model were to keep
the slope fixed but to estimate the intercept. To meet this end, the linear
predictor was used as an offset variable, thus fixing the coefficient at
unity, so that the intercept was the only free parameter. The resulting
estimate for the intercept indicates the deviation from the original one,
and this model renders recalibrated predicted probabilities.18 Only data
from patients with complete information were used, and the resulting
numbers of correct classifications overall and in each outcome group
were determined.
Finally, novel logistic regression models were developed on the basis
of the variables that had been selected for the previous models, namely,
age and NIHSS score. The thresholds for categorization of patients were
Table 1. Estimated Regression Coefficients of the Original,
Recalibrated, and Novel Models Predicting Functional Recovery
and Survival
Original Recalibrated Novel
Functional recovery
Intercept 5.782 6.148 5.112
Age 0.049 0.049 0.046
NIHSS* 0.272 0.272 0.196
Survival
Intercept 7.040 7.373 5.445
Age 0.049 0.049 0.037
NIHSS* 0.155 0.155 0.092
*Overall score on the NIHSS.
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determined anew on the basis of the outcome frequencies in the data sets
as before17 to compare the resulting numbers of correct classifications
with those from the previous approaches. Because in the different
approaches the outcome of the same patients is predicted by different
prognostic models, we tested differences in the overall accuracies by
McNemar’s test, and we present the estimated differences with 95% CIs
according to Zhou and Qin.25 The analyses were performed with the R
software environment, version 2.3.1, with the Design package by Harrell.26
Results
Characteristics of the 5843 patients in the VISTA data set
meeting the specified inclusion criteria are presented in Table 2.
The BI after 90 days was recorded in 4441 patients, and 1970 of
these had recovered, whereas 2471 had not functionally recov-
ered. In another 978 patients without a recorded BI, information
on mortality within this time frame was available. Of these, 607
(62.1%) had died, so that these were additionally classified as
not functionally recovered. Therefore, for the functional recov-
ery model, data from 5048 patients were available, of whom
1970 had recovered and 24716073078 had either not recov-
ered or had died. Independent of the availability of the BI, there
was information on mortality for 5419 patients, of whom 4441
had survived and 978 were deceased. As shown in Table 2, age
was slightly higher than in the original data sets (mean differ-
ence0.71 years, 95% CI0.04 to 1.38); similarly, neurologic
impairment was less severe in the original sample (mean
difference6.50, 95% CI6.15 to 6.84). In the VISTA data set,
the proportion of women was higher than in the original data set
(difference in proportions3.4%, 95% CI0.7% to 6.0%).
Further details on patients’ characteristics are given in the
original publications.17,19
In the most stringent approach, the original models were
applied to predict the patients’ outcomes, and the receiver
Figure 1. Nomograms for (A) the model predicting functional recovery (BI 95) vs no functional recovery (BI 95) or mortality and for
(B) the model predicting survival vs mortality.
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operating characteristics are shown in Figure 2. According to the
original thresholds, 3678 patients (72.9%) were classified cor-
rectly overall in the functional recovery model, with a more correct
prediction of patients who did not recover than in those who did
(90.8% and 44.9%, respectively). According to the survival model,
3815 patients (70.4%) were classified correctly overall, with
56.3% of patients who died and 73.5% of patients who survived.
In the second approach, the original models were recali-
brated by using an adapted intercept. The deviations of the
original and the new intercepts were estimated to be 0.36
(95% CI0.29 to 0.44) for the functional recovery model and
0.33 (95% CI0.26 to 0.41) for the survival model, showing
that the predicted probabilities for favorable outcome in both
models were systematically too low (see Figures 3 A and 3B).
Using the recalibrated models (see Table 1 for estimated
regression coefficients and Figures 3C and 3D for calibration
plots) led to slightly altered classifications, with overall 3735
patients (74.0%) being classified correctly for the functional
recovery model (86.1% who did not recover and 55.1% who
did recover). For the survival model, 4054 patients (74.8%)
were predicted correctly (46.7% of patients who died and
81.0% of patients who patients). Thus, the accuracies were
higher than in the original model (for the functional recovery
model, difference1.1%, 95% CI0.4% to 1.9%, 2-sided
P0.0026, and for the survival model, difference4.5%,
95% CI3.7% to 4.5%, 2-sided P2.21016).
Finally, novel logistic regression models were developed
by estimating new regression coefficients of the previously
identified parameters (Table 1, right column). Thereby the
recovery model predicted 3736 patients (74.0%) correctly
overall (78.8% of those who did not recover and 66.6% of
those who did). In the survival model, 4212 patients (77.7%)
were classified correctly (38.2% of those who died and 86.4%
of those who survived). Compared with the original model,
the accuracy was higher overall (for functional recovery,
difference1.2%, 95% CI0.1% to 2.3%, 2-sided
P0.0452; for survival, difference7.4%, 95% CI6.4% to
8.3%, 2-sided P2.21016). Although there was no differ-
ence in accuracies for the functional recovery model between
the novel and the recalibrated prognosis (difference0.0%,
95% CI0.8% to 0.9%, 2-sided P1.0000), accuracy was
higher in the novel than in the recalibrated survival model
overall (difference2.9%, 95% CI2.3% to 3.6%, 2-sided
P2.21016). However, this was mostly due to a more
correct classification of the patients who survived, whereas
40% of patients who died were predicted correctly.
Discussion
An early, simple, and reliable model to calculate the progno-
sis of likely outcome in stroke patients is desirable and useful,
for both clinical practice and research purposes. We previ-
ously developed and externally validated models that fulfilled
Table 2. Patients’ Characteristics in Original and VISTA Data Sets
Original Data VISTA Data
BI, n (%)
95 1025 (58.4%) 1970 (44.4%)
95 729 (41.6%) 2471 (55.6%)
Survival, n (%)
Yes 1588 (90.5%) 4441 (82.0%)
No 166 (9.5%) 978 (18.0%)
Sex, n (%)
Female 716 (40.8%) 2583 (44.2%)
Male 1038 (59.2%) 3260 (55.8%)
Age, y
Mean (SD) 68.1 (12.7) 68.8 (12.3)
NIHSS*
Mean (SD) 6.9 (6.2) 13.4 (6.5)
*Overall score on the NIHSS.
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Figure 2. Receiver operating characteristics for (A) the model
predicting functional recovery (BI 95) vs no functional recovery
(BI 95) or mortality and for (B) the model predicting survival vs
mortality based on the original model. Areas under the curves
(AUC) are given with standard errors (S.E.).
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these criteria.17 Starting from a set of 16 variables that had
been identified in a systematic literature search, we devised a
final model that included age and overall NIHSS score only,
both as linear variables.17 Thus, we generalized our already
validated prognostic models in another phase III prognostic
factor study by following the recommendations of Altman
and colleagues.27,28 This generalization aims at increased
acceptance of the prognostic models by demonstrating their
substantial predictive value in another population. Our prog-
nostic models have been developed from the traditional
statistical approach of logistic-regression models; these have
the advantage of being simple to interpret and illustrate in a
nomogram and have been shown to be at least as good in
prediction as alternative machine learning approaches.29
In the present study, we have shown that our models, when
transferred to more or less selected study populations, are
able to correctly predict functional independence and mortal-
ity after 3 months in 70% of all patients. Because patients
from controlled studies in VISTA were systematically pre-
dicted slightly too pessimistically by the original models, we
performed a recalibration of the models in which the intercept
of the model was adapted to the new data. As a result, the
overall accuracy of prediction increased in the functionally
independent or surviving patients but decreased for patients
with a poorer outcome. This can be explained by the fact that
the recalibrated models had a cutoff set according to the new
outcome distribution rather than equal sensitivity and speci-
ficity. It needs to be emphasized that even though the refined
models led to a significant increase of 57 and 241 patients
being predicted correctly in comparison with the original
models, the relative improvement in percentage is rather
modest (1% and 4.5%, respectively). Also, with the adapted
intercepts, the estimated accuracies of the refined models may
be optimistic, so that in another independent sample, im-
provement over the original models may not stand.
Interestingly, estimating the coefficients anew does not
improve the prediction over the recalibrated model for functional
recovery, indicating a good discrimination of the original model.
For the survival model, the higher overall accuracy of the new
model was accompanied by a worse prediction of deceased
patients, so that this is not recommended over the recalibrated
model for clinical practice. To a greater extent than for the
refined models, it should be considered that the latter models
with novel parameter estimates need to be validated in different
samples to guarantee generalization.
This study has some limitations. First, the predictive accura-
cies identified in the most stringent approach may not seem to
justify relying on the given prediction over clinical judgment.
However, we have previously shown that clinical judgment by
the admitting neurology resident is inferior to our models and
correctly predicted 70% of all patients.17 Also, a simple
recalibration of the intercept considerably improved the overall
correct prediction of our models in VISTA. Second, our models
do not consider imaging or laboratory investigations, which
were impossible to obtain in our large original cohorts within an
early time frame and a standardized evaluation protocol. Instead,
we decided to focus our models on variables that are readily
accessible and require neither a sophisticated technique nor a
rigorous time frame. However, other studies have shown the
prognostic value of magnetic resonance imaging in acute
stroke,9–11 which has also become an inclusion criterion in
thrombolysis trials with desmoteplase.30,31 Third, we have now
shown the external validity of our models in 2 different popu-
lations of stroke patients, namely, patients admitted to German
neurology departments with an acute stroke unit17 and patients
included in controlled clinical trials.19 This by no means repre-
sents the entire universe of stroke patients, and subsequent
studies are required to investigate the validity in other stroke
populations.
Figure 3. Calibration plots delineating observed
vs predicted outcome probabilities from the
original models predicting functional recovery
(A) and survival (B) and from the recalibrated
models predicting functional recovery (C) and
survival (D). Dots represent the calibration
curves created using lowess smoothers, and
lines show the ideal calibration.
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Simple prognostic models may play an important role in
future randomized trials in acute stroke. Patients included in
these studies should have a high chance of incomplete recovery
but low probability of mortality, which is usually unaffected by
new medical treatment options. Therefore, it may be desirable to
exclude patients with a high a chance of complete spontaneous
recovery and those with a high chance of mortality because their
data are unlikely to contribute to a measurable treatment effect.
We have previously shown that overall sample size and trial time
can be reduced by eliminating potential nonresponders and by
increasing the number of eligible patients compared with con-
ventional study designs.3 Alternatively, prognosis-adjusted end
points could be defined for patients with a high probability of
functional recovery, as have already been used in several acute
stroke trials.32–34
In conclusion, our original models can readily be applied in
clinical practice and research settings with sufficient predic-
tive accuracy, even in different patient populations. For
patients included in clinical trials, a simple recalibration helps
to adjust for a different case mix and is indeed recommended
if a large data set is available.
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